Accumulating evidence indicates that gene amplification in the ALK domain or the acquisition of activating point mutations have been found in neuroblastoma, anaplastic large cell non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and non-small-cell lung cancer (NSCLC) (Golding et al., 2018; Indini et al., 2020). The gene discussed is ALK; the disease is non-small cell lung carcinoma.